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Abstract
Rationale: Smoking cessation is the most important intervention for
patients with chronic obstructive pulmonary disease (COPD). What
leads smokers with COPD to quit smoking remains unknown.
Objectives:We sought to examine the association between respiratory
symptoms and other markers of COPD severity with intention to quit
smoking among a cohort of patients with probable COPD.
Methods:We conducted a cross-sectional study of subjects with COPD
or fixed airflow obstruction clinically diagnosed on the basis of pulmonary
function testing.The subjectswere identified in theCOPDOutcomes-based
Network for Clinical Effectiveness and Research Translation multicenter
registry. The primary outcomewas the intention to quit smokingwithin the
next 30 days (yes or no), which was examined using model building with
multivariable logistic regression, clustered by study site.
Measurements and Main Results:We identified 338 current
smokers with COPD via the registry. Of these subjects, 57.4% (n = 194)
had confirmed airflow obstruction based on pulmonary function testing.
Nearly one-third (29.2%; n = 99) intended to quit smoking in the next
30 days. In adjusted analyses, compared with subjects without airflow
obstruction based on pulmonary function testing, subjects with Global
Initiative for Chronic Obstructive Lung Disease stage I/II COPD were
more likely to be motivated to quit (odds ratio [OR], 1.85; 95% confidence
interval [CI], 1.37–2.49),withnoassociation found for subjectswithGlobal
Initiative for Chronic Obstructive Lung Disease stage III/IV disease.
Among the entire cohort, frequent phlegm (OR, 2.10; 95% CI, 1.22–3.64),
cough (OR, 1.74; 95%CI, 1.01–2.99), wheeze (OR, 1.73; 95%CI, 1.09–3.18),
and higher modified Medical Research Council dyspnea score
(OR, 1.26 per point; 95% CI, 1.13–1.41) were associated with increased
odds of intending to quit smoking. Low self-reported healthwas associated
with decreased odds of intending to quit (OR, 0.75; 95% CI, 0.62–0.92).
Conclusions: Frequent cough, phlegm, wheeze, and shortness of breath
were associatedwith intention to quit smoking in thenext 30days,with a less
clear relationship for severity of illness gradedbypulmonary function testing
and self-rated health. These findings can be used to inform the content of
tobacco cessation interventions to provide a more tailored approach for
patients with respiratory diseases such as COPD.
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Tobacco use remains a major contributor
to poor health, particularly among older
smokers and smokers with chronic
obstructive pulmonary disease (COPD)
(1). After decades of successful tobacco
control policies, the rate of decline in the
prevalence of smoking in the United States
has slowed (2). One possible explanation is
that tobacco use is increasingly
concentrated among patients who are less
motivated to quit or are less able to do so
with conventional cessation support,
making new insights into the factors that
prompt a quit attempt a priority.
In previous studies, researchers
reported that health concerns play a
significant role in the intention and
motivation to quit smoking (3, 4), with
some indication that respiratory symptoms
are particularly important (5). Diagnosis of
a smoking-related condition can prompt
individuals to make a quit attempt (6).
Patients with COPD, one of the smoking-
related conditions most directly attributable
to tobacco use, are at very high risk for poor
health due to ongoing tobacco abuse,
including increased risk for lung cancer,
worsening lung function, cardiovascular
disease (7), and progressive respiratory
symptoms. This population has been shown
to benefit greatly from smoking cessation
(8, 9). Unfortunately, the prevalence of
smoking among individuals with COPD
remains about twice as high as in the
population as a whole (10). However,
smokers with COPD have similar quit rates
with treatment and a similar number of
quit attempts when compared with smokers
in general (11).
Despite the importance of cessation
among patients with tobacco-related
respiratory diseases, factors associated with
the intention to quit smoking among patients
with COPD are poorly understood. The
primary goal of this study was to examine the
association of respiratory symptoms, severity
of airflow obstruction (AFO), and other
markers of COPD disease severity with the
intention to quit smoking in a cohort of
patients with clinically diagnosed COPD and
a subset of patients with confirmed fixed
AFO. The Health Belief Model suggests that
cues to action are an important part of
making a change in health behavior.
Therefore, we hypothesized that respiratory
symptoms would predict the intention to quit
smoking in the near term. Some of the results
of this study were reported previously in the
form of an abstract (12).
Methods
Design, Participants, and Data Source
We conducted a cross-sectional study of
patients who were identified as having
probable COPD. The complete methods for
the identification of the study population
have previously been published (13). In
brief, potential subjects were selected via
probability-based sampling from the COPD
Outcomes-based Network for Clinical
Effectiveness and Research Translation
(CONCERT) DataHub (14). The DataHub
comprised 220,000 patients 40 years of age
or older identified using a comprehensive
electronic health record database from
2006–2010, drawn from seven sites
representing academic, private, and
integrated healthcare organizations.
Patients were identified for inclusion in the
database via one of three methods: (1)
identification of COPD-related codes in the
International Classification of Diseases,
Ninth Revision; (2) a medication list that
included one or more respiratory-related
treatments (short- or long-acting
b-agonists, short- or long-acting
anticholinergics, inhaled corticosteroids, or
formulations containing a combination of
these medications); or (3) spirometry
demonstrating fixed AFO.
A stratified sample of patients was
invited to complete an in-person study
visit, and they provided written informed
consent to participate. Of those who were
contacted and eligible (n = 3,350), a total of
1,206 patients (36%) agreed to participate
and completed data collection procedures.
Trained study personnel administered a
questionnaire to collect information on
demographics, self-reported comorbid
conditions, symptoms, tobacco history, and
intention to quit smoking. Patients
completed several validated scales for
assessment of dyspnea, functional status,
and health-related quality of life.
Post-bronchodilator spirometry was
performed and interpreted per the
American Thoracic Society standards (15),
with measurements of height and weight
taken at the visit. The presence and
frequency of phlegm, cough, and wheeze
were assessed by subject report using
standardized instruments by asking
whether subjects often or usually
experienced a given symptom. The
instrument was adapted from previously
described epidemiologic tools for the
purposes of this study (16). Subjects were
limited to patients who identified smoking
in the past 30 days (“smokers”). All
smokers who completed the study visit
were included in the primary analysis, with
secondary analysis restricted to subjects
with fixed AFO based on post-
bronchodilator FEV1/FVC less than or
equal to 0.7. All subjects completed
and submitted informed consent forms
(VA Puget Sound IRB 00207).
Predictors
The exposures included severity of AFO as
measured by Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stage
(17); respiratory symptoms; exacerbation of
COPD within the past 3 months; use of
home oxygen; and measures of dyspnea,
functional status, and self-reported health.
We used GOLD stage based on spirometry,
rather than the new GOLD classification,
because we lacked a full year of history to
categorize subjects according to the new
GOLD classification and because we
wanted to examine exacerbation history
and symptoms independently. Our primary
measurement of shortness of breath was
done using the modified Medical Research
Council (mMRC) dyspnea scale (18). The
mMRC dyspnea scale is a simple 5-point
scale corresponding to activities that provoke
dyspnea, with scores ranging from 0 (short of
breath only with heavy exertion) to
4 (shortness of breath with dressing or minor
activities). Assessment of phlegm, cough, and
wheeze was performed using standardized
questionnaires as described above.
We measured health status using the
self-reported health measure of the EuroQol
(EQ)-5D-5L (19), which asks subjects to
assign a number to their health, ranging
from 0 (worst) to 100 (best). We measured
functional limitation using the Patient
Reported Outcomes Measurement
Information System (PROMIS)-43 scale
(20, 21). The PROMIS functional limitation
scale is normalized against the general
population, with a score of 50
corresponding to average and a lower score
corresponding to lower physical function.
Our final assessment of dyspnea was done
using the Functional Assessment of
Chronic Illness Therapy (FACIT) scale
(22, 23). The FACIT scale for dyspnea is
normalized against a population of subjects
with self-reported COPD, with a score of 50
corresponding to average and a higher
score corresponding to more dyspnea.
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Scores were categorized in tertiles, with the
less symptomatic subjects serving as the
referent group.
Outcome
We were interested in capturing all smokers
who expressed interest in quitting within the
next 30 days. Therefore, we assessed
intention to quit smoking with a single
question, “Are you seriously considering
quitting smoking?,” with a response of
“yes, within 30 days” considered positive.
This query is very similar to the assessment
of the preparation stage of tobacco
cessation that has been used in a number of
studies (24, 25), though our assessment was
purposefully more inclusive to better
mirror the assessment performed in clinical
practice. A statement of intention to quit
within the next 30 days has been found to
correlate with other markers of motivation
and self-efficacy for tobacco cessation (26).
While intention and motivation are
conceptually different measures, an
intention to change is a necessary step in
the process of changing a behavior.
Confounders
We selected confounders a priori, and these
included age, race, sex, educational
attainment, current smoking intensity, and
time spent with other smokers in the home.
Because comorbid conditions may
influence intention to quit smoking, both
independently and through worsening
symptoms and frequency of healthcare
contacts, we assessed a number of
self-reported comorbidities (listed in
Table 1) as potential confounders.
Statistical Analysis
We used Stata 13 software (StataCorp,
College Station, TX) for statistical analysis.
We used chi-square tests and t tests to assess
unadjusted associations. We performed
logistic regression modeling. We built
individual models for each symptom and
marker of disease severity, adjusted for the
confounders listed above, with GOLD stage
excluded as a confounder from the model
in which it was the primary predictor.
Analyses were clustered by site using robust
standard errors with a Huber-White
sandwich estimator. We assessed each
comorbidity for association with the
outcome in an individual model, with those
attaining a value of P< 0.15 in bivariate
models considered for inclusion in the final
models. Model building was repeated for
the subjects with fixed AFO on spirometry.
An a value less than or equal to 0.05 was
considered significant. No adjustment was
made for multiple comparisons. Model fit
was assessed with the Hosmer-Lemeshow
goodness-of-fit test and the area under the
curve, which ranged from 0.71 to 0.74 for
all the models.
Results
Of 3,350 potential subjects, 1,206 (36%)
subjects completed the study visit. Of these
1,206 participants, 338 (28%) identified as
current smokers and were included in our
analysis (Figure 1). Overall, 29.2% (n = 99)
of identified smokers indicated an intention
Table 1. Characteristics of current smokers in two motivational stages among a cohort
of patients with clinically diagnosed chronic obstructive pulmonary disease
Smokers, Intending to Quit within 30 d?
Variable Yes (n = 99) No (n = 239) P Value
Age, yr 60.3 (7.4, 44–85) 61.0 (8.25, 42–85) 0.496
Male sex 57 (57.6) 132 (55.7) 0.769
Race
White 61 (61.6) 171 (71.3) 0.213
Black 30 (30.3) 56 (23.3)
Other 8 (8.1) 13 (5.4)
Education 0.436
Less than high school 16 (16.2) 41 (17.3)
High school 21 (21.2) 65 (27.4)
Above high school 62 (62.6) 131 (55.3)
Smoking behavior
Current smoking, cigarettes/d 10.2 (9.1, 1–40) 15.5 (10.7, 1–70) ,0.001
Pack-years 45.3 (32.0, 0.3–171) 49.3 (28.7, 2.6–182) 0.868
Hours with other smokers
in the home
2.3 (4.8, 0–24) 3.3 (6.6, 0–24) 0.164
Symptoms and disease severity
Phlegm most days 56 (56.6) 102 (42.5) 0.018
Cough most days 68 (68.7) 143 (60.4) 0.152
Wheeze often 68 (68.7) 135 (56.3) 0.034
mMRC dyspnea scale* 1.55 (1.06, 0–4) 1.39 (1.05, 0–4) 0.222
Prescribed medications
for breathing
74 (74.7) 169 (70.4) 0.421
Ever prescribed home oxygen 24 (24.2) 37 (15.4) 0.054
COPD exacerbation in the
past 3 mo
13 (13.1) 30 (12.5) 0.874
FACIT dyspnea 46.4 (9.32, 27.7–72.2) 45.2 (8.4, 27.7–72.2) 0.245
EQ-5D-5L: self-reported health† 70.9 (18.2, 20–100) 60.0 (20.1, 10–100) 0.037
PROMIS physical function 40.0 (6.4, 26.5–57.8) 40.1 (7.2, 26.5–57.8) 0.931
Self-report of COPD‡ 72 (72.7) 174 (73.4) 0.909
GOLD stage 0.433
No fixed airflow obstruction 40 (40.4) 105 (44.3)
I/II 43 (43.4) 85 (35.9)
III/IV 16 (16.2) 47 (19.8)
Comorbid conditions
Lung cancer 3 (3.0) 9 (3.8)
Diabetes 17 (17.2) 64 (26.7) 0.062
CHF 18 (18.2) 41 (17.1) 0.808
Stroke 14 (14.1) 38 (15.8) 0.094
Depression 57 (57.6) 127 (52.9) 0.434
CAD 35 (35.4) 89 (37.6) 0.710
Kidney disease 14 (14.1) 47 (19.8) 0.177
OSA 32 (32.3) 51 (21.5) 0.031
Definition of abbreviations: CAD = coronary artery disease; CHF = congestive heart failure;
COPD = chronic obstructive pulmonary disease; EQ = EuroQol; FACIT = Functional Assessment of
Chronic Illness Therapy; GOLD =Global Initiative for Chronic Obstructive Lung Disease;
mMRC=modified Medical Research Council; OSA = obstructive sleep apnea; PROMIS = Patient
Reported Outcomes Measurement Information System.
Values presented are mean (SD, range) or number (percent). Missingness was less than 2% for all
variables. P values were calculated using chi-square t tests.
*Missing for four subjects.
†Reported on 0–100 scale, worst to best.
‡Includes COPD, chronic bronchitis, and emphysema.
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to quit smoking in the next 30 days. In
unadjusted analyses, subjects who intended
to quit smoking in the next 30 days smoked
fewer cigarettes daily, reported more
respiratory symptoms, and were more likely
to experience sleep apnea. There were no
observed differences in dyspnea or physical
function, though smokers who intended to
quit reported higher self-rated health on the
EQ-5D-5L (Table 1).
Association of Symptoms and
Disease Severity
In adjusted analyses, GOLD stage
demonstrated a U-shaped association with
intention to quit smoking. In comparison
with smokers without fixed AFO on
spirometry, subjects with GOLD stage I/II
COPD were more likely to intend to quit
smoking in the next 30 days (odds ratio
[OR], 1.85; 95% confidence interval
[CI], 1.37–2.49), whereas subjects with
GOLD stage III/IV disease were not
(OR, 1.11; 95% CI, 0.66–1.87). Several
respiratory symptoms were associated with
almost double the odds of intending to quit
smoking within the next 30 days: phlegm
on most days (OR, 2.10; 95% CI, 1.22–3.64),
cough (OR, 1.74; 95% CI, 1.01–2.99), and
frequent wheeze (OR, 1.73; 95% CI,
1.09–3.18).
For each point higher on the mMRC
dyspnea scale, corresponding to more
dyspnea, we found higher odds of intending
to quit smoking in the next 30 days (OR,
1.26; 95% CI, 1.13–1.41). Subjects with the
lowest self-rated health on the EQ-5D-5L
were less likely to intend to quit smoking in
both groups (OR, 0.75; 95% CI, 0.62–0.92;
and OR, 0.67; 95% CI, 0.49–0.92) (Table 2).
These same relationships were observed
among subjects with fixed AFO based on
pulmonary function testing, though wheeze
was not statistically significant.
Shortness of breath as measured by the
FACIT dyspnea scale was not associated
with intention to quit smoking, though there
was a non–statistically significant trend for
an association between intending to quit
and more dyspnea (OR, 1.84; 95% CI,
0.92–3.70). Other markers of disease
severity were not associated with intention
to quit smoking in the next 30 days among
the overall cohort, including physical
function as measured by the PROMIS
physical function scale, exacerbation of
COPD within the past 3 months, the use of
respiratory medications, and having been
prescribed home oxygen at any time.
However, among subjects with fixed AFO,
use of home oxygen (OR, 1.79; 95% CI,
1.04–3.09) and a moderate but not severe
amount of physical limitation based on the
PROMIS scale (OR, 2.05; 95% CI,
1.06–3.97) were both associated with
increased odds of intending to quit
smoking in the next 30 days (Table 2).
Discussion
Within this cohort of current smokers,
comprising both those with probable COPD
and those with confirmed COPD, near-term
intention to quit smoking was associated
with symptoms suggestive of chronic
bronchitis and shortness of breath, but it
was less clearly associated with other
measures reflective of COPD severity. These
results were found among the overall cohort
with a clinical diagnosis of COPD as well
as among the subjects with fixed AFO based
on pulmonary function testing. These
findings suggest that symptom burden is
more highly associated with the intention to
quit smoking than with other measures of
COPD severity, such as a history of
exacerbations, more severe lung disease
based on spirometry, or use of home oxygen.
More than hospitalizations or the use of
medication, frequent symptoms may be
socially disruptive and difficult to conceal or
ignore.
In previous studies (27–29), patients
with bronchitic symptoms such as phlegm,
cough, and wheeze realized significant
improvements in these symptoms if they
were successful at smoking cessation.
Patients who are motivated to quit smoking
in the setting of these symptoms may
therefore be counseled regarding the
likelihood of improvement if they are
successful.
Typical physician-based tobacco
counseling is focused on the “dangers of
tobacco use” (30), such as the increased
risks for cancer, worsening lung function,
oxygen dependence, and death. The Health
Belief Model suggests that the motivation to
change a potentially dangerous behavior
depends on a number of factors, including
the patient’s belief regarding susceptibility
to a particular health concern (31). While
physicians are well aware of the potential
long-term risks for their patients, patients
may not fully perceive their risk for these
future complications. Misinformation on
the risks of tobacco use is common among
smokers, and it is detrimental to quit
attempts (32, 33). However, symptoms that
are readily apparent on a daily basis are
harder to deny and may therefore lead to
more quit attempts.
These data support the use of a tailored
approach to tobacco cessation among older
smokers with and at risk for COPD, an
approach focused on more immediately
tangible rewards, and suggest that the most
opportune time for providers to discuss
smoking cessation may be when patients
report cough, phlegm, wheeze, or shortness
of breath. Although it is a necessary first
step, intention to quit smoking does not
necessarily translate into a successful
attempt to do so (34). Focusing on
symptoms as a motivating factor for a
cessation attempt may be beneficial by
1,206 subjects who completed testing
339 current cigarette smokers
1,008 ever smokers of cigarettes 669 former smokers
188 never smokers
10 cigar smokers
3,350 patients contacted and eligible
from the
CONCERT DataHub
Figure 1. Results of patient selection from the COPD Outcomes-based Network for Clinical
Effectiveness and Research Translation (CONCERT) DataHub.
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providing a more immediate, concrete, and
positive reason for a behavior change (35).
This fits within the framework of the “five
R’s” of motivational interviewing
(relevance, risks, rewards, roadblocks, and
repeat), an evidence-based method
designed to help motivate the unmotivated
smoker or aid the motivated smoker
struggling with turning thought into action
(36). Recent data indicate that providers are
already much more likely to provide
counseling and assistance to smokers with
COPD, with undiagnosed or asymptomatic
smokers assisted at a much lower rate (37).
Although symptoms may provide an
excellent opportunity for a clinician to
initiate a discussion of smoking cessation,
an absence of symptoms does not relieve
the clinician from recommending or
providing smoking cessation therapies.
We also observed that patients with
GOLD stage I/II disease were more likely to
intend to quit in the near term than were
those with GOLD stage III/IV disease, and
that subjects with the lowest self-reported
health were less likely to endorse an
intention to quit smoking in the next
30 days. The finding that subjects with mild
to moderate COPD were more likely than
those without AFO to intend to quit
smoking was unsurprising.
However, it is concerning that smokers
with more severe COPD and subjects with
worse self-reported health were less likely to
intend to quit smoking. These data are
consistent with those in prior studies which
showed that older smokers and smokers
with COPD were less likely to recognize and
endorse the benefits of cessation, and
believed that they themselves would find
quitting too hard (38–40). We may have
identified a subgroup of smokers with
COPD at the highest risk of ongoing danger
due to tobacco use. Our findings persist
despite adjustment for heaviness of tobacco
use, time spent with other smokers, and
other markers of socioeconomic status.
Therefore, the subgroup of smokers with
heavy tobacco use, other smokers in the
home, and low socioeconomic status in
addition to COPD and respiratory
symptoms may represent the highest-risk
group for ongoing tobacco abuse and
warrant further investigation.
An alternative explanation for our
findings is that smokers who were more
motivated to quit may have stopped
smoking at an earlier disease stage, leaving a
population of “hard-core” smokers at
higher GOLD stages. Again, this
underscores the need for tailored
treatments for smokers with significant
pulmonary disease, aimed at getting them
to quit earlier in the disease process. In
previous studies examining interventions
tailored to older smokers, researchers found
improved cessation rates (41). Such
personalized materials may be beneficial for
patients with lung diseases.
Table 2. Adjusted odds ratios of endorsing intention to quit smoking within next 30 days among current smokers with or without
fixed airflow obstruction, by symptoms and markers of disease severity
Variable All Smokers (n = 338) Subjects with COPD Based on PFT (n = 194)
OR 95% CI P Value OR 95% CI P Value
GOLD stage
0 (no COPD) Reference — —
I–II (mild to moderate) 1.85 1.37–2.49 ,0.001 Reference
III–IV (severe to very severe) 1.11 0.66–1.87 0.694 0.67 0.38–1.17 0.157
Phlegm most days 2.10 1.22–3.64 0.007 2.41 1.37–4.24 0.034
Cough most days 1.74 1.01–2.99 0.045 2.15 1.06–4.36 0.034
Wheeze frequently 1.73 1.09–3.18 0.023 1.98 0.94–4.18 0.071
mMRC dyspnea scale, per point higher* 1.26 1.13–1.41 ,0.001 1.22 1.05–1.42 0.008
Exacerbation in past 3 mo 0.92 0.63–1.33 0.645 1.62 0.64–4.08 0.308
Prescribed home oxygen 1.85 0.90–3.76 0.090 1.79 1.04–3.09 0.036
Reported physician-diagnosed COPD,
emphysema, or chronic bronchitis
0.97 0.69–1.38 0.874 1.34 0.73–2.44 0.348
FACIT dyspnea score†
<40 Reference Reference
40–49 1.35 0.80–2.28 0.264 1.42 0.57–3.53 0.453
>50 1.84 0.92–3.70 0.087 2.00 0.86–4.68 0.105
PROMIS score, physical function‡
>42 Reference Reference
35–42 1.47 0.85–2.55 0.168 2.05 1.06–3.97 0.033
<35 1.12 0.52–2.42 0.775 1.06 0.51–2.19 0.881
EQ-5D-5L, self-reported health, 0–100
from worst to best
>80 Reference Reference
60–80 1.35 0.80–2.26 0.257 1.00 0.70–1.44 0.984
<60 0.75 0.62–0.92 0.005 0.67 0.49–0.92 0.012
Definition of abbreviations: CI = confidence interval; COPD = chronic obstructive pulmonary disease; EQ = EuroQol; FACIT = Functional Assessment of
Chronic Illness Therapy; GOLD =Global Initiative for Chronic Obstructive Lung Disease; mMRC=modified Medical Research Council; OR = odds ratio;
PFT = pulmonary function testing; PROMIS = Patient Reported Outcomes Measurement Information System.
Models are adjusted for age, race, education, cigarettes smoked daily, GOLD stage, hours spent with another smoker, and comorbidities, clustered by
site. Bold type indicates statistically significant values.
*n = 333 and n = 191 for all smokers and subjects with COPD, respectively, due to missingness.
†Normalized against an average of 50, with higher score meaning more dyspnea.
‡Normalized against an average of 50, with lower score meaning worse physical function.
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Strengths and Limitations
Our study has several limitations. Inference
is limited due to the cross-sectional nature of
the data. Smoking status was determined by
self-report and was not biochemically
confirmed. While information on the
number of cigarettes smoked daily was
available, additional testing of level of
addiction was not performed. The stated
intent to quit smoking was measured at a
single time point, with the possibility of
overreporting due to social desirability.
However, recent data suggest that subjects
do not frequently overreport a desire to quit
smoking, regardless of the modality of
measurement (42). Measures of recent
exacerbations, comorbidities, and use of
oxygen were based on patient report, which
may have introduced recall bias by severity
of disease. The recall period was within
accepted time periods for more accurate
recall, and we would anticipate this bias to
be nondifferential to our outcome.
Although the subjects who completed
the study visit appeared to be representative
of the DataHub as a whole, we had a
relatively low response rate, which may have
introduced selection bias. Subjects who
agree to participate in research may differ
from the population with and at risk for
COPD overall. We would anticipate that
these subjects might be more engaged in
healthcare and therefore more likely to
report an intention to quit smoking in the
next 30 days. However, the proportion of
our subjects (28.2%) who indicated an
intention to quit smoking in the next 30 days
was nearly identical to that found in a
national population-based study of subjects
with self-reported COPD (37). Finally, we
were able to assess only intent to quit
smoking, not whether those intentions led
to success.
Our study has a number of strengths.
We selected patients from a large database
across multiple sites and cities, improving
the generalizability of the results to the
population of smokers with and at risk for
COPD. We had access to spirometry, the
gold standard for the diagnosis of COPD, as
well as to detailed demographic data. Last,
we had access to a number of highly
validated measures of symptom burden and
physical limitation.
Conclusions
Respiratory symptoms consistent with
chronic bronchitis were significantly
associated with the intention to quit
smoking. This suggests that a focus on the
daily experience of smokers—more than on
the other downstream complications—may
be helpful when encouraging quit attempts
for all smokers. This information can
particularly be used to help tailor cessation
support materials and counseling for
symptomatic smokers and smokers with
COPD. Addressing tobacco use when
respiratory symptoms are present may
improve quit rates among a population of
chronically ill and potentially recalcitrant
smokers. n
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